Back to search

McMaster University

Examination of the Contributions of Proprotein Convertase Subtilisin/Kexin Type 9 to Breast Cancer Tumorigenesis and a Multigene Signature SIG27 Relevant to PCSK9 in Assessing the Risk of Breast Cancer Poor Prognosis

Abstract

dc:description.abstract

Breast cancer (BC) is the most frequently diagnosed malignancy and the leading cause of cancer mortality in females. Hormone therapy with tamoxifen (TAM) is a fundamental treatment for estrogen receptor-positive (ER+) BC, the predominant subtype of BC, accounting for 70% of BC incidences; however, approximately 40% of patients develop resistance via mechanisms that are not fully understood, and triple-negative breast cancer (TNBC; ER<1%, PR<1% and HER2 negative) lacks effective therapies. While complex mechanisms contribute to the challenges in managing ER+ BC and TNBC, cholesterol availability commonly promotes aggressiveness of both subtypes of BC. In this regard, my studies revealed that proprotein convertase subtilisin/kexin type 9 (PCSK9), a major regulator of cholesterol homeostasis, promotes ER+ BC and TNBC progression largely via its physiological activities in cholesterol regulation. The relevance of PCSK9 in ER+ BC has not been directly studied. Although PCSK9 was reported in TNBC, whether PCSK9 oncogenic actions are related to its cholesterol regulating properties remains unclear. My PhD studies thus fulfilled the knowledge gap. In an analysis of 1,097 TCGA (The Cancer Genome Atlas) BC tissues and 114 corresponding normal tissues, upregulation of PCSK9 mRNA expression was demonstrated in BC and ER+ BC. To study PCSK9’s functionality in promoting ER+ BC, I established MCF7 ER+ BC lines with stable expression of empty vector (EV), PCSK9, its gain-of-function (GOF) mutant D374Y, and the loss-of-function (LOF) PCSK9 mutant Q152H. Compared to EV, PCSK9 and D374Y promoted colony formation, augmented intracellular cholesterol accumulation, and provided a survival benefit against TAM cytotoxicity along with dramatic upregulation of CYP17A1 and CYP19A1. All above changes were abolished by Q152H. Given both CYP17A1 and CYP19A1 are rate-limiting enzymes in estrogen biosynthesis, a process that requires cholesterol, the above observations strongly suggest the involvement of PCSK9’s physiological activities in promoting MCF7 cell growth and TAM resistance by enhancing estrogen receptor (ER) signaling in vitro. We further demonstrated this potential in vivo. In orthotopic xenografts generated by MCF7 EV and MCF7 D374Y cells, MCF7 D374Y tumors exhibited markedly accelerated growth and conferred resistance to TAM treatment compared to MCF7 EV tumors. Mechanistically, nude mice bearing MCF7 tumors increased circulating PCSK9 (circ-PCSK9) and circ-E2 (estrogen); MCF7 D374Y tumors upregulated CYP17A1, CYP19A1, nuclear ER content, and AKT activation (pAKT). In response to TAM treatment, MCF7 D374Y tumors displayed strong resistance along with robust upregulations of nuclear ER, CYP17A1, SRC-3, and MUC1. Collectively, we showed that PCSK9’s physiological activity increases cholesterol availability and ER signaling, and thereby confers resistance to TAM. My studies also showed the essential contributions of PCSK9 cholesterol-regulating activity in enhancing TNBC tumorigenesis and progression. We produced stable TNBC cell lines expressing empty vector (EV), PCSK9, the gain-of-function PCSK9 mutant D374Y, and the loss-of-function mutant Q152H in human BT549 and murine 4T1 cells. The respective PCSK9 and D374Y cells displayed elevations in proliferation and colony formation in vitro. The 4T1 PCSK9 and D374Y cells produced rapidly growing allografts in the mammary fat pad of BALB/c mice, which dynamically metastasized to the lungs and ovaries compared with 4T1 EV and Q152H allografts. The 4T1 PCSK9 and D374Y tumors were cholesterol-enriched and upregulated KI67, pAKT, and estrogen receptor (ER) expression. Mice bearing 4T1 PCSK9 and D374Y tumors exhibited dramatically increased circulating estrogen. In ovariectomized BALB/c mice, 4T1 D374Y allografts exhibited 1) aggressive growth and systemic metastasis, 2) upregulations in ER, pAKT, and intratumoral cholesterol contents, and 3) increases in circulating estrogen compared to 4T1 EV tumors. RNA-sequencing revealed downregulation of CD8+ T cell activation, B cell activation, and other immune signaling in 4T1 PCSK9 and D374Y tumors compared to 4T1 EV allografts. Tumors with increases in PCSK9 activity showed decreased CD8+, granzyme B-positive cells, and increased PD-1, PD-L1, PD-L2, TIGIT, LGALS9 and PVRIG immune checkpoint expression. Compared to 4T1 EV tumors, 4T1 PCSK9 and D374Y tumors shared 104 differentially expressed genes: Overlap104, which robustly predicted poor overall survival in TNBC across three large datasets with ROC-AUC values of 0.8-0.87. Collectively, PCSK9 promotes TNBC progression along with increases in cholesterol accumulation, estrogen production, and immunosuppression. Given the association of PCSK9 and its network signature Overlap104 with TNBC immune evasion features, we reasoned a relationship between Sig27, a multigene signature reflecting cancer’s immune evasion features, which our laboratory has recently shown in prostate cancer and renal cell carcinoma, and PCSK9 as well as Overlap104. Indeed, we were able to show high-level correlations (R > 0.5) between Sig27 with both PCSK9 and Overlap104 in multiple BC cohorts. Sig27 exhibited substantial alterations in 4T1 D374Y tumors compared to EV tumors, demonstrating consistent dysregulation across 13,103 primary BCs, 60 metastases, and 780 normal breast tissues. It categorized BC mortality risk comparable to OncotypeDX and MammaPrint while forecasting poor prognosis across 21 cancer types. Importantly, Sig27 differed from current assays in biological significance—OncotypeDX and MammaPrint indicated mitotic progression, while Sig27 encompassed immune regulation, with its principal components (FPR3, LAMP3, FAM65B) predominantly localized to tumor-associated macrophages and exhibiting a strong correlation with various immune checkpoints; its immune-centric refinement (Sig27IM) forecasted pathological complete response to PD-1/PD-L1 inhibitors and demonstrated a robust correlation with recognized immune signatures (CTL, Merck18, TIDE, STAT1-sig). These findings collectively designate PCSK9 may serve as a mediator of endocrine-therapy resistance in ER+ BC, cholesterol-driven progression and checkpoint-mediated immune evasion in TNBC, and as an immune-centric prognostic framework related to Sig27. Collectively, my study provides the first comprehensive analysis showing that PCSK9 promotes ER+ BC and TNBC by enhancing cholesterol availability, which relies on PCSK9 cholesterol regulating properties. Give these properties are targeted by FDA-approved PCSK9 inhibitors (evolocumab, alirocumab and inclisiran), my PhD research outlined a scientific basis for utilizing these inhibitors in managing ER+ BC and TNBC.

Degree

thesis:*
Department dc:contributor.department
Medical Sciences
Year dc:date.issued
2026

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Su, Yingying
Advisor dc:contributor.advisor
  • Tang, Damu

Identifiers

dc:identifier.*

Chain of custody

source
Harvested from
McMaster University
Base URL
macsphere.mcmaster.ca/server/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
related terms
citation

Su, Yingying. Examination of the Contributions of Proprotein Convertase Subtilisin/Kexin Type 9 to Breast Cancer Tumorigenesis and a Multigene Signature SIG27 Relevant to PCSK9 in Assessing the Risk of Breast Cancer Poor Prognosis. 2026. https://hdl.handle.net/11375/33585